title: Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
abstract: BACKGROUND
  LDL and hs-CRP are risk factors for vascular events and can be modified by Statin.
  
  
  OBJECTIVE
  To evaluate the baseline hs-CRP of a certain Thai population who would need Atorvastatin, to evaluate the dose response of Atorvastatin toward LDL and hs-CRP level, and to evaluate the efficacy and safety of different types of Atorvastatin.
  
  
  METHODS
  Subjects, who needed Statin therapy, were randomized to receive either 20 mg of Berlin(B)-Atorvastatin(R) or Pfizer(P)-Atorvastatin(R). The cross over took place after 8 weeks of therapy and continued for 16 weeks. Baseline blood tests were compared to 8 and 16 weeks. The effect of two brands of 20 mg Atorvastatin toward serum lipid, LFT, muscle enzyme and hs-CRP were compared.
  
  
  RESULTS
  One hundred and ten subjects aged between 20-75 years enrolled in the present study. Fifty-four and 56 patients were randomized to group A and B. Baseline total cholesterol, LDL, HDL, and TG were 251, 174, 55, and 160 mg/dl respectively. There was a wide variation of baseline hs-CRP level. One hundred and seven patients completed this 16 weeks study. Atorvastatin 20 mg lowered TC by 32%, LDL 44% and hs-CRP 10% at 16 weeks for the entire study (p < 0.003). The effect of either Atorvastatin the lipid profiles and hs-CRP were different. There was no significant change in LFT or muscle enzyme.
  
  
  CONCLUSIONS
  Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. The two different types of Atorvastatin (group A and B) have similar effect on both safety and efficacy.
authors.affiliation: Ramthibodi Hospital, Mahidol University, Bangkok, Thailand. rasbb@mahidol.ac.th
authors.forename: Sarana
authors.initials: S
authors.lastname: Boonbaichaiyapruck
authors.forename: Sayan
authors.initials: S
authors.lastname: Cheepudomwit
authors.forename: Pradit
authors.initials: P
authors.lastname: Panjavenin
authors.forename: Taworn
authors.initials: T
authors.lastname: Suthichaiyakul
authors.forename: Worachart
authors.initials: W
authors.lastname: Moleelerkpoom
authors.forename: Thanawat
authors.initials: T
authors.lastname: Benjanuwatra
authors.forename: Bancha
authors.initials: B
authors.lastname: Sukanandachai
authors.forename: Adisai
authors.initials: A
authors.lastname: Buakhamsri
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000187:drug effects*; D008076:Cholesterol, HDL / Q000187:drug effects; D008078:Cholesterol, LDL / Q000187:drug effects*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D012307:Risk Factors; D013785:Thailand; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin